论文部分内容阅读
Multiple myeloma is a post-germinal center B-cell malignancy characterized by an accumulation of abnormal clonal plasma cells in the bone marrow.Clinically the patients develop anaemia, renal impairment, lytic bone lesions and hypercalcaemia.Despite improvement in treatment, the disease is incurable.Many clinical and biological aspects of cancer are driven and affected by underlying genetic abnormalities.In multiple myeloma, the study of genetics has been hampered by the low proliferation of the clonal cells with the consequent inability to obtain informative karyotype.With the advent of technology, from ability to study genetics in non-dividing interphase cells to the current state-of-the-art high resolution global genomic analysis using microarrays, the understanding of myeloma genomics have grown exponentially.Today, genetic is established an important prognostic factors, and allow for risk-stratified treatment and the development of new therapies targeting specific abnormalities deregulated by the genetic abnormalities.Myeloma genetics has therefore elevated from a research tool to an important clinical tool.In the future, we will be able to use genomics to further refine tumor and patient heterogeneity towards individualized therapy for myeloma.In this talk, I hope to highlight work done by us and others towards achieving this lofty goal.